FDA Brief

Warning letters Food

FDA warning letter to

Enlifta, LLC

High riskIssued Feb 18, 2021Posted Feb 19, 2021Center for Food Safety and Applied Nutrition (CFSAN)

FDA warned Enlifta that it sells unapproved new drugs for depression and anxiety through its website and Amazon.

What happened

FDA reviewed Enlifta's websites in December 2020 and February 2021 and its linked Amazon product pages. FDA found claims and testimonials saying “Enlifta Mood Elevator” and “Enlifta Anxiety” treat depression and anxiety. FDA says these claims make the supplements drugs, and that they are unapproved new drugs and misbranded because they lack adequate directions for safe use by laypeople.

What FDA found

  1. The products are drugs because the website and Amazon claims say they are intended to treat depression and anxiety.

    section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)]
  2. The products are unapproved new drugs because they are not generally recognized as safe and effective for those uses and have no FDA approval.

    sections 201(p), 301(d), and 505(a) of the Act [21 U.S.C. §§ 321(p), 331(d), 355(a)]
  3. The products are misbranded because they lack adequate directions for use for conditions that a layperson cannot safely diagnose or treat without a licensed practitioner.

    section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]; 21 CFR § 201.5
  4. Introducing or delivering these misbranded drugs into interstate commerce violates the Act.

    section 301(a) of the Act [21 U.S.C. § 331(a)]

What FDA wants

FDA asks Enlifta to take prompt action to correct the violations and to notify FDA in writing within 15 working days of the steps taken, with supporting documents, or explain why the products are not violations.

Who should pay attention

  • online supplement sellers making disease-treatment claims
  • retailers and marketplaces hosting supplement listings
  • consumers using supplements for depression or anxiety

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk